Unknown

Dataset Information

0

Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.


ABSTRACT: Dysregulation of the cell cycle characterizes many cancer subtypes, providing a rationale for developing cyclin-dependent kinase (CDK) inhibitors. Potent CDK2 inhibitors might target certain cancers in which CCNE1 is amplified. However, current CDK2 inhibitors also inhibit CDK1, generating a toxicity liability. We have used biophysical measurements and X-ray crystallography to investigate the ATP-competitive inhibitor binding properties of cyclin-free and cyclin-bound CDK1 and CDK2. We show that these kinases can readily be distinguished by such inhibitors when cyclin-free, but not when cyclin-bound. The basis for this discrimination is unclear from either inspection or molecular dynamics simulation of ligand-bound CDKs, but is reflected in the contacts made between the kinase N- and C-lobes. We conclude that there is a subtle but profound difference between the conformational energy landscapes of cyclin-free CDK1 and CDK2. The unusual properties of CDK1 might be exploited to differentiate CDK1 from other CDKs in future cancer therapeutic design.

SUBMITTER: Wood DJ 

PROVIDER: S-EPMC6344228 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.

Wood Daniel J DJ   Korolchuk Svitlana S   Tatum Natalie J NJ   Wang Lan-Zhen LZ   Endicott Jane A JA   Noble Martin E M MEM   Martin Mathew P MP  

Cell chemical biology 20181121 1


Dysregulation of the cell cycle characterizes many cancer subtypes, providing a rationale for developing cyclin-dependent kinase (CDK) inhibitors. Potent CDK2 inhibitors might target certain cancers in which CCNE1 is amplified. However, current CDK2 inhibitors also inhibit CDK1, generating a toxicity liability. We have used biophysical measurements and X-ray crystallography to investigate the ATP-competitive inhibitor binding properties of cyclin-free and cyclin-bound CDK1 and CDK2. We show that  ...[more]

Similar Datasets

| S-EPMC6589648 | biostudies-literature
| S-EPMC7990704 | biostudies-literature
| S-EPMC2668819 | biostudies-literature
| S-EPMC4839568 | biostudies-literature
| S-EPMC2709845 | biostudies-literature
| S-EPMC10728085 | biostudies-literature
| S-EPMC5856554 | biostudies-literature
| S-EPMC8902891 | biostudies-literature
| S-EPMC3567213 | biostudies-literature
| S-EPMC9209526 | biostudies-literature